MYOTUBULAR TRUST — grant history
Latest income
£147k
Grants listed (FY2025)
4
Listed grants total
£249k
Accounts grants total
£254k
listed grants reconcile with the accounts totalextracted from its FY2025 accounts
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Radboud 2025 | — | £10k |
| up | Sick Kids | £36k | £164k |
| up | Inserm(Buj Bello) 2023-25 | £21k | £55k |
| down | Great Ormond Street (GOSH) | £249k | £21k |
| not listed | Hnia at Inserrn | £33k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Sick Kids | FY2025 | £164k | Studying liver disease in X-linked myotubular myopathy |
| Inserm(Buj Bello) 2023-25 | FY2025 | £55k | Next generation gene therapy |
| Great Ormond Street (GOSH) | FY2025 | £21k | An Advanced Multi-Organoid Platform for Therapy Modelling in X-Linked Myotubular Myopathy |
| Radboud 2025 | FY2025 | £10k | Research grant |
| Great Ormond Street (GOSH) | FY2024 | £249k | An Advanced Multi-Organoid Platform for Therapy Modelling in X-Linked Myotubular Myopathy (Prof Francesco Saverio Tedesco and Dr Valentina Maria Lionello at University College London) |
| Sick Kids | FY2024 | £36k | Studying liver disease in X-linked myotubular myopathy (Dr Jim Dowling) |
| Hnia at Inserrn | FY2024 | £33k | Next generation gene therapy (Dr Ana Buj Bello) |
| Inserm(Buj Bello) 2023-25 | FY2024 | £21k | Next generation gene therapy (Dr Ana Buj Bello) |
| Newcastle University re Treat NMD | FY2024 | amount not stated | Contributed to the first ever Congenital Myopathies Masterclass |
| MDUK | FY2023 | £300k | Grant to Dr Jim Dowling at Sick Kids to study liver disease in X-linked myotubular myopathy, in partnership with MDUK. Note: The text states MDUK is contributing £60,000 to the overall grant of £300,000. However, the SOFA shows £16,151 in restricted funds for research, and Note 4 lists specific grants. The £300,000 figure is the total project value, not necessarily the amount paid by Myotubular Trust in this specific accounting period or as a direct grant to MDUK. Let's look closer at Note 4. |
| Hnia at Inserrn | FY2022 | £39k | mTORC pathway research |
| Tamoxifoen Protocol | FY2022 | £31k | Tamoxifen clinical trial (UK arm) |
| Newcastle University re Treat NMD | FY2022 | £29k | Patient Registry software development |
| Research Consultancy | FY2022 | £8k | Not specified in note, likely general research support |
| Research Consultancy | FY2022 | £2k | Not specified in note, likely general research support |
| Hnia at Inserrn | FY2021 | £29k | mTORC pathway research |
| Newcastle University re Treat NMD | FY2021 | £8k | Standards of Care meeting / TREAT-NMD collaboration |
| Tamoxifoen Protocol | FY2021 | £2k | Tamoxifen clinical trial (UK arm) |
| Research Consultancy | FY2021 | £2k | Consultancy services |